Botulinum Toxin for Trigeminal Neuralgia

  • Arunmozhimaran Elavarasi
  • Vinay Goyal


The American Academy of Neurology and the European Federation of Neurological Societies (AAN/EFNS) guidelines for the management of trigeminal neuralgia (TGN) suggest anticonvulsant medications as first line therapy; the surgical options utilized drug-refractory cases [1]. However, many patients are refractory to drugs, and surgical treatment may not be feasible owing to associated comorbid illnesses. Interventional procedures on the peripheral trigeminal nerve or on the Gasserian ganglion may not always be possible because of the unavailability of skilled practitioners. Botulinum neurotoxin (BoNT) is a promising mode of treatment, which can help such patients and provide pain relief.


  1. 1.
    Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, Zakrzewska JM, American Academy of Neurology Society, European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–28.CrossRefGoogle Scholar
  2. 2.
    Macdonald TE, Helma CH, Shou Y, Valdez YE, Ticknor LO, Foley BT, et al. Analysis of Clostridium botulinum serotype E strains by using multilocus sequence typing, amplified fragment length polymorphism, variable-number tandem-repeat analysis, and botulinum neurotoxin gene sequencing. Appl Environ Microbiol. 2011;77:8625–34.CrossRefGoogle Scholar
  3. 3.
    Scaglione F. Conversion ratio between Botox(R), Dysport(R), and Xeomin(R) in clinical practice. Toxins (Basel). 2016;8:pii:E65.CrossRefGoogle Scholar
  4. 4.
    Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7:31–9.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155–88.PubMedGoogle Scholar
  6. 6.
    Verderio C, Grumelli C, Raiteri L, Coco S, Paluzzi S, Caccin P, et al. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic. 2007;8:142–53.CrossRefGoogle Scholar
  7. 7.
    Oh HM, Chung ME. Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel). 2015;7:3127–54.CrossRefGoogle Scholar
  8. 8.
    Colhado OC, Boeing M, Ortega LB. Botulinum toxin in pain treatment. Rev Bras Anestesiol. 2009;59:366–81.CrossRefGoogle Scholar
  9. 9.
    Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol. 2002;25:260–2.CrossRefGoogle Scholar
  10. 10.
    Allam N, Brasil-Neto JP, Brown G, Tomaz C. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain. 2005;21:182–4.CrossRefGoogle Scholar
  11. 11.
    Zuniga C, Diaz S, Piedimonte F, Micheli F. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr. 2008;66:500–3.CrossRefGoogle Scholar
  12. 12.
    Turk Boru U, Duman A, Boluk C, Coskun Duman S, Tasdemir M. Botulinum toxin in the treatment of trigeminal neuralgia: 6-month follow-up. Medicine (Baltimore). 2017;96:e8133.CrossRefGoogle Scholar
  13. 13.
    Morgan JC, Iyer SS, Moser ET, Singer C, Sethi KD. Botulinum toxin A during pregnancy: a survey of treating physicians. J Neurol Neurosurg Psychiatry. 2006;77:117–9.CrossRefGoogle Scholar
  14. 14.
    Paul M. Controversy: botulinum toxin in pregnancy. J Cutan Aesthet Surg. 2009;2:4–5.CrossRefGoogle Scholar
  15. 15.
    Newman WJ, Davis TL, Padaliya BB, Covington CD, Gill CE, Abramovitch AI, et al. Botulinum toxin type A therapy during pregnancy. Mov Disord. 2004;19:1384–5.CrossRefGoogle Scholar
  16. 16.
    Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013;36:146–50.CrossRefGoogle Scholar
  17. 17.
    Wu C, Xie N, Liu H, et al. A new target for the treatment of trigeminal neuralgia with botulinum toxin type A. Neurol Sci. 2018;39:599–602.CrossRefGoogle Scholar
  18. 18.
    Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32:443–50.CrossRefGoogle Scholar
  19. 19.
    Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14:92.CrossRefGoogle Scholar
  20. 20.
    Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15:65.CrossRefGoogle Scholar
  21. 21.
    Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, et al. Therapeutic efficacy and safety of botulinum toxin A therapy in trigeminal neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17:63.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Arunmozhimaran Elavarasi
    • 1
  • Vinay Goyal
    • 2
  1. 1.Department of NeurologyJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)PuducherryIndia
  2. 2.Department of NeurologyNeurosciences Centre, All India Institute of Medical Sciences (AIIMS)New DelhiIndia

Personalised recommendations